961 related articles for article (PubMed ID: 26928243)
1. Pathogenesis of Nonalcoholic Steatohepatitis.
Machado MV; Diehl AM
Gastroenterology; 2016 Jun; 150(8):1769-77. PubMed ID: 26928243
[TBL] [Abstract][Full Text] [Related]
2. Bioactive Lipid Species and Metabolic Pathways in Progression and Resolution of Nonalcoholic Steatohepatitis.
Musso G; Cassader M; Paschetta E; Gambino R
Gastroenterology; 2018 Aug; 155(2):282-302.e8. PubMed ID: 29906416
[TBL] [Abstract][Full Text] [Related]
3. Progression from Nonalcoholic Fatty Liver to Nonalcoholic Steatohepatitis Is Marked by a Higher Frequency of Th17 Cells in the Liver and an Increased Th17/Resting Regulatory T Cell Ratio in Peripheral Blood and in the Liver.
Rau M; Schilling AK; Meertens J; Hering I; Weiss J; Jurowich C; Kudlich T; Hermanns HM; Bantel H; Beyersdorf N; Geier A
J Immunol; 2016 Jan; 196(1):97-105. PubMed ID: 26621860
[TBL] [Abstract][Full Text] [Related]
4. Pathogenesis of NASH: How Metabolic Complications of Overnutrition Favour Lipotoxicity and Pro-Inflammatory Fatty Liver Disease.
Farrell GC; Haczeyni F; Chitturi S
Adv Exp Med Biol; 2018; 1061():19-44. PubMed ID: 29956204
[TBL] [Abstract][Full Text] [Related]
5. Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals.
Suppli MP; Rigbolt KTG; Veidal SS; Heebøll S; Eriksen PL; Demant M; Bagger JI; Nielsen JC; Oró D; Thrane SW; Lund A; Strandberg C; Kønig MJ; Vilsbøll T; Vrang N; Thomsen KL; Grønbæk H; Jelsing J; Hansen HH; Knop FK
Am J Physiol Gastrointest Liver Physiol; 2019 Apr; 316(4):G462-G472. PubMed ID: 30653341
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of disease progression in nonalcoholic fatty liver disease.
Jou J; Choi SS; Diehl AM
Semin Liver Dis; 2008 Nov; 28(4):370-9. PubMed ID: 18956293
[TBL] [Abstract][Full Text] [Related]
7. Nonalcoholic Fatty Liver Disease vs. Nonalcoholic Steatohepatitis: Pathological and Clinical Implications.
Boutari C; Lefkos P; Athyros VG; Karagiannis A; Tziomalos K
Curr Vasc Pharmacol; 2018; 16(3):214-218. PubMed ID: 28676025
[TBL] [Abstract][Full Text] [Related]
8. Metabolic drivers of non-alcoholic fatty liver disease.
Bence KK; Birnbaum MJ
Mol Metab; 2021 Aug; 50():101143. PubMed ID: 33346069
[TBL] [Abstract][Full Text] [Related]
9. Nonalcoholic Steatohepatitis.
Suzuki A; Diehl AM
Annu Rev Med; 2017 Jan; 68():85-98. PubMed ID: 27732787
[TBL] [Abstract][Full Text] [Related]
10. A lipidomic analysis of nonalcoholic fatty liver disease.
Puri P; Baillie RA; Wiest MM; Mirshahi F; Choudhury J; Cheung O; Sargeant C; Contos MJ; Sanyal AJ
Hepatology; 2007 Oct; 46(4):1081-90. PubMed ID: 17654743
[TBL] [Abstract][Full Text] [Related]
11. The Role of Cholesterol in the Pathogenesis of NASH.
Ioannou GN
Trends Endocrinol Metab; 2016 Feb; 27(2):84-95. PubMed ID: 26703097
[TBL] [Abstract][Full Text] [Related]
12. Pathophysiology of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis.
Manne V; Handa P; Kowdley KV
Clin Liver Dis; 2018 Feb; 22(1):23-37. PubMed ID: 29128059
[TBL] [Abstract][Full Text] [Related]
13. S100A9: A Potential Biomarker for the Progression of Non-Alcoholic Fatty Liver Disease and the Diagnosis of Non-Alcoholic Steatohepatitis.
Liu X; Wang Y; Ming Y; Song Y; Zhang J; Chen X; Zeng M; Mao Y
PLoS One; 2015; 10(5):e0127352. PubMed ID: 25993652
[TBL] [Abstract][Full Text] [Related]
14. [Cholesterol metabolism and non-alcoholic steatohepatitis].
Ma ZZ; Lu LG
Zhonghua Gan Zang Bing Za Zhi; 2016 Aug; 24(8):623-627. PubMed ID: 27788713
[TBL] [Abstract][Full Text] [Related]
15. Novel Aspects in the Pathogenesis of Nonalcoholic Steatohepatitis.
Gentilini A; Caligiuri A; Provenzano A; Marra F
Curr Mol Med; 2016; 16(8):710-720. PubMed ID: 27774883
[TBL] [Abstract][Full Text] [Related]
16. Lipidomics in pathogenesis, progression and treatment of nonalcoholic steatohepatitis (NASH): Recent advances.
Musso G; Saba F; Cassader M; Gambino R
Prog Lipid Res; 2023 Jul; 91():101238. PubMed ID: 37244504
[TBL] [Abstract][Full Text] [Related]
17. Natural History of Simple Steatosis or Nonalcoholic Fatty Liver.
De A; Duseja A
J Clin Exp Hepatol; 2020; 10(3):255-262. PubMed ID: 32405182
[TBL] [Abstract][Full Text] [Related]
18. Metabolism dysregulation induces a specific lipid signature of nonalcoholic steatohepatitis in patients.
Chiappini F; Coilly A; Kadar H; Gual P; Tran A; Desterke C; Samuel D; Duclos-Vallée JC; Touboul D; Bertrand-Michel J; Brunelle A; Guettier C; Le Naour F
Sci Rep; 2017 Apr; 7():46658. PubMed ID: 28436449
[TBL] [Abstract][Full Text] [Related]
19. [An Overview of NAFLD/NASH in Japan].
Kim SR; Kim KI
Yakugaku Zasshi; 2016; 136(4):565-72. PubMed ID: 27040340
[TBL] [Abstract][Full Text] [Related]
20. Noninvasive diagnostic criteria for nonalcoholic steatohepatitis based on gene expression levels in peripheral blood mononuclear cells.
Kado A; Tsutsumi T; Enooku K; Fujinaga H; Ikeuchi K; Okushin K; Moriya K; Yotsuyanagi H; Koike K
J Gastroenterol; 2019 Aug; 54(8):730-741. PubMed ID: 30830270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]